[
    [
        {
            "time": "",
            "original_text": "凯莱英(002821.SZ)参股子公司拟引入产业资本增资扩股以充实资本实力",
            "features": {
                "keywords": [
                    "凯莱英",
                    "参股子公司",
                    "产业资本",
                    "增资扩股",
                    "资本实力"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)参股子公司拟引入产业资本增资扩股以充实资本实力",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "小分子“王者”凯莱英再冲港股，重仓大分子业务，要跟药明生物抢地盘",
            "features": {
                "keywords": [
                    "凯莱英",
                    "港股",
                    "小分子",
                    "大分子业务",
                    "药明生物"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "小分子“王者”凯莱英再冲港股，重仓大分子业务，要跟药明生物抢地盘",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "药明康德领衔，这个医药细分会成为十年十倍的机会么？",
            "features": {
                "keywords": [
                    "药明康德",
                    "医药细分",
                    "十年十倍",
                    "机会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德领衔，这个医药细分会成为十年十倍的机会么？",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]